These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 7903931

  • 1. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
    Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW.
    Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
    [Abstract] [Full Text] [Related]

  • 2. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM, Lamberts SW.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [Abstract] [Full Text] [Related]

  • 3. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
    [Abstract] [Full Text] [Related]

  • 4. Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells.
    Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SW.
    Endocrinology; 1992 Aug; 131(2):571-7. PubMed ID: 1322274
    [Abstract] [Full Text] [Related]

  • 5. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L.
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [Abstract] [Full Text] [Related]

  • 6. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
    Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S.
    J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
    [Abstract] [Full Text] [Related]

  • 7. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
    Djordjijevic D, Zhang J, Priam M, Viollet C, Gourdji D, Kordon C, Epelbaum J.
    Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
    [Abstract] [Full Text] [Related]

  • 8. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW.
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [Abstract] [Full Text] [Related]

  • 9. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

  • 10. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release.
    Karashima T, Cai RZ, Schally AV.
    Life Sci; 1987 Aug 24; 41(8):1011-9. PubMed ID: 2886886
    [Abstract] [Full Text] [Related]

  • 11. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW.
    Endocrinology; 1995 Sep 24; 136(9):3698-706. PubMed ID: 7649075
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL, Spaziante R, Giusti M, Schettini G.
    Clin Endocrinol (Oxf); 2003 Jul 24; 59(1):115-28. PubMed ID: 12807513
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
    Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J.
    J Clin Endocrinol Metab; 1992 Aug 24; 75(2):540-6. PubMed ID: 1353505
    [Abstract] [Full Text] [Related]

  • 14. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas.
    Hofland LJ, de Herder WW, Waaijers M, Zuijderwijk J, Uitterlinden P, van Koetsveld PM, Lamberts SW.
    J Clin Endocrinol Metab; 1999 Sep 24; 84(9):3336-43. PubMed ID: 10487708
    [Abstract] [Full Text] [Related]

  • 15. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P.
    Neuroendocrinology; 2006 Sep 24; 83(3-4):258-63. PubMed ID: 17047391
    [Abstract] [Full Text] [Related]

  • 16. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH.
    J Clin Endocrinol Metab; 2000 Feb 24; 85(2):781-92. PubMed ID: 10690891
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S.
    J Clin Invest; 1997 Nov 01; 100(9):2386-92. PubMed ID: 9410919
    [Abstract] [Full Text] [Related]

  • 18. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion.
    Shimon I, Rubinek T, Hadani M, Alhadef N.
    J Endocrinol Invest; 2004 Sep 01; 27(8):721-7. PubMed ID: 15636423
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A.
    J Clin Endocrinol Metab; 2001 Jul 01; 86(7):2976-81. PubMed ID: 11443154
    [Abstract] [Full Text] [Related]

  • 20. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A.
    Neuroendocrinology; 2001 May 01; 73(5):344-51. PubMed ID: 11399907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.